Bedrijfsoverzicht
Microbot Medical Inc. is a specialized medical device manufacturer dedicated to transforming endovascular procedures through the deployment of advanced robotic technology, with its primary offering being the LIBERTY endovascular robotic surgical system that enables physicians to perform catheter-based procedures remotely. Operating within the Healthcare sector and specifically in the Medical Instruments & Supplies industry, the company leverages this technological focus to address complex clinical needs without relying on traditional open surgical methods. As of the latest reported data, the enterprise carries a market capitalization of $173.94M and employs a workforce of 43 individuals to execute its strategic operations. The current market cap relative to the reported annual revenue of N/A indicates a valuation structure heavily reliant on future technological adoption rather than established historical sales volumes, positioning the firm as a high-potential but pre-profitability stage entity within the niche medical robotics landscape.
Financiële gezondheid
The company reported a Net Income of $-13,142,000 and an EBITDA of $-14,696,000 over the trailing twelve months, while the Revenue figure remains N/A; the substantial gap between these negative income metrics and the reported revenue indicates a cost structure where operating expenses significantly exceed gross revenues, resulting in a pre-tax loss that persists despite top-line activity. This financial position is further characterized by a Free Cash Flow of $-8,316,375, which suggests that the company is currently burning cash to fund research, development, and commercialization efforts rather than generating liquidity for operational expansion or shareholder returns. Analysis of the three primary margins reveals a Gross Margin of 0.0%, an Operating Margin of 0.0%, and a Profit Margin of 0.0%, collectively indicating that the company has not yet achieved profitability where gross revenue exceeds the sum of direct costs and operating overheads. Regarding capital structure, the firm holds a Cash balance of $78.59M against a Debt liability of $865,000, resulting in a Debt to Equity ratio of 1.11, which presents a complex balance sheet scenario where high leverage metrics coexist with significant cash reserves. The Current Ratio stands at 23.33, a figure that points to an extremely strong short-term liquidity position, suggesting the company possesses ample current assets to cover its short-term obligations many times over. Finally, the Return on Equity is -32.4% and the Return on Assets is -21.0%, metrics that reveal that management effectiveness in generating returns on invested capital is currently negative, reflecting the inherent losses typical of companies in the growth phase of the product lifecycle.
Waarderingsbeoordeling
The valuation metrics present a forward P/E of -7.85 while the trailing P/E (TTM) is N/A, a disparity that implies earnings are currently negative and thus the traditional price-to-earnings multiple cannot be calculated on a historical basis, rendering forward estimates the primary indicator for future expected earnings trajectory if profitability is achieved. The Price to Book ratio is 2.24, which indicates that the market values the company at more than double its book value per share, suggesting a premium assigned to the underlying intellectual property and technological assets that are not fully captured in standard accounting book values. Alternative valuation metrics such as the Price to Sales ratio of N/A and an EV/EBITDA of -6.55 further illustrate that the company is not being valued based on current sales multiples or earnings multiples, as the negative EV/EBITDA confirms the unprofitable status and the absence of a sales multiple suggests the lack of comparable revenue data for standard valuation models. The stock's price volatility is contextualized by a 52-Week High of $4.67 and a 52-Week Low of $1.60, framing the trading range within which the security has moved over the past year. The Beta value of 1.19 indicates that the stock's price volatility is slightly higher than the broader market, meaning it is expected to move with greater amplitude than the general market index during periods of price fluctuation.
Growth & Income
The reported Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, preventing a direct comparison of whether earnings are growing faster or slower than revenue, but the absence of these growth rates underscores the company's current stage of development where historical year-over-year expansion data is not yet available for analysis. Regarding income distribution, the company does not pay a dividend, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, which confirms that the firm retains all available cash flow to reinvest into growth initiatives such as product development and market expansion rather than distributing income to shareholders. The 0.0% payout ratio is entirely consistent with a Net Income of $-13,142,000, as a negative earnings base precludes any sustainable dividend payment, necessitating a strategy focused on capital preservation and growth investment. Overall, the growth and income profile is defined by a complete absence of dividend income and undefined historical growth rates, directing investor focus entirely on the potential for future commercialization success and the conversion of current losses into future profitability.